ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2025
[Lung Cancer with Pulmonary Embolism: Evidence-based Progress in Anticoagulation Assessment and Management].
Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is the malignant tumour with the highest incidence and mortality rates globally. Patients with lung cancer face a high risk of developing venous thromboembolism (VTE), particularly pulmonary embolism (PE). This not only prolongs hospital stays and increases inpatient costs but also severely impacts patient survival and quality of life. Current risk assessment models for PE and bleeding risk in lung cancer patients remain limited in efficacy, posing challenges for clinicians in selecting anticoagulation or preventing bleeding. Additionally, anticoagulation management involves complex issues such as drug interactions and managing special populations. Based on existing literature, this review summarizes the clinical risk assessment and management of anticoagulation and bleeding, the selection of anticoagulants, and secondary prevention strategies for lung cancer patients with PE, to provide a reference for individualized clinical diagnosis and treatment. .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.